Table 7.

Summary statistics for the clinician efficacy scores assessed more than 24 hours after surgery

Response	Visits	Robenacoxib (s.c. + oral)	Meloxicam s.c. + oral placebo	P value (Mann–Whitney test)	Quotient robenacoxib:meloxicam (RMANCOVA)		P value (RMANCOVA)	Transformation for RMANCOVA analysis
		Mean (SD)	Mean (SD)		Mean	95% CI		Exponential	P value for normality (Shapiro-Wilks test)
Global investigator score (primary end point)	V5	1.86 (1.61)	1.98 (1.91)	0.93	0.968	0.682–1.316	0.84	0 (log)	0.53
Posture	V5	0.70 (0.68)	0.78 (0.74)	0.72	1.007	0.527–1.693	0.98	−1 (reciprocal)	<0.0001
Behaviour	V5	0.42 (0.59)	0.54 (0.84)	1.0	1.064	0.565–1.786	0.82	−0.5 (reciprocal of square root)	<0.0001
Pain on palpation/manipulation	V5 & VF	0.44 (0.62)	0.52 (0.84)	0.65	1.032	0.768–1.343	0.82	0.5 (square root)	<0.0001
Overall pain control	V5 & VF	0.76 (0.62)	0.76 (0.71)	0.49	1.143	0.807–1.567	0.42	0.5 (square root)	<0.0001
Inflammation intensity	VF	0.15 (0.04)	0.25 (0.06)	0.16	1.642	0.752–3.695	0.18	0 (log)	<0.0001

CI: confidence interval; s.c.: subcutaneous; VF: final visit.

Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. Data are from assessments at V5 and VF.

Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.

The global investigator score (the primary end point) ranged from 0 to 9. All other end points (secondary end points) ranged from 0 to 3.